All Articles

Real-world data from a retrospective analysis of octreotide long-acting release (LAR) dosing patterns on treatment persistence in patients with symptomatic metastatic neuroendocrine tumors (NETs) indicate that physician experience and treatment at tertiary centers has a significant impact on dose selection and treatment persistence.

Findings of a comparative retrospective analysis indicate that first-line octreotide long-acting release (LAR) and lanreotide treatment was associated with similar progression-free survival (PFS) and biochemical response in patients with metastatic, well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Results of the CLARINET FORTE trial showed that lanreotide autogel (LAN) 120 mg at escalating dosing frequency (every 14 days) was associated with promising progression-free survival (PFS) benefit and no new safety issues in patients with progressive pancreatic or midgut neuroendocrine tumors (NETs).

Results of the prospective phase 2 ATLANT study indicate that lanreotide autogel (LAN) plus temozolomide (TMZ) combination therapy was efficacious and well-tolerated in patients with progressive thoracic neuroendocrine tumors (NETs).

Preliminary results of an ongoing dose-escalation and expansion phase 1 (Duet 1; NCT03411915) trial indicate that the anti–somatostatin receptor type 2 (SSTR2) × anti-CD3 bispecific antibody XmAb18087 was well-tolerated and accompanied by sustained T-cell activation in patients with advanced neuroendocrine tumors (NETs).

A retrospective analysis of a large database of grade 3 gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) identified clinically relevant prognostic factors that could potentially inform clinical decisions in this setting.

Results of a retrospective analysis of first-line chemotherapy regimens indicate that non–platinum/etoposide regimens may provide a significant progression-free survival (PFS) benefit versus platinum/etoposide regimens for patients with grade 3 neuroendocrine tumors (NETs).

Findings of a population-based retrospective cohort study indicate that the risk for cancer-specific death exceeds the risk for noncancer death; however, patients with nonmetastatic neuroendocrine tumors (NETs) may have a higher risk for noncancer deaths.

Patient-reported outcomes data of the XERMELO Patient Registry indicate that patients with neuroendocrine tumors (NETs) experiencing carcinoid syndrome (CS) reported improvement in CS symptom control and satisfaction with telotristat ethyl (TE) treatment, as well as reduced activity impairment and work productivity losses after 6 months of treatment.

Results of a retrospective study indicate that the 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) ± bevacizumab regimen is active in patients with aggressive and heavily pretreated pancreatic neuroendocrine tumors (NETs) who have progressed on prior capecitabine + temozolomide chemotherapy.